Several state and private organizations in France, including the wound dressing specialist Urgo, announced on Friday the creation of artificial skin intended for transplantation in their laboratory. However, this experience still requires confirmation through clinical trials.
Guirec Le Lus, president of the Urgo group, which specializes in wound healing, emphasized that 'for the first time in the world we have been able to create artificial skin ready for transplantation in a laboratory.'
This technological breakthrough was achieved in collaboration with partners gathered in a consortium that includes CNRS, Université Lyon 1, the Stem Cell Research Center, the French Blood Institution, and Dassault Systèmes. According to Le Lus, this could be the beginning of a 'medical revolution.'
The long-term goal is to provide surgeons with pre-made artificial skin without the need to take cells from the patient themselves. This skin will be stored at a temperature of -150 degrees Celsius (°C) and will be ready for immediate use in the operating room after thawing for patients with severe injuries, such as victims of extensive burns.
The consortium stated in its announcement that 'after thawing, the cells remain alive and functional.'
Currently, the most frequently used surgical method is autotransplantation, which involves removing healthy skin from the patient themselves and then applying it to burned areas. The technology they implemented is based on 'using universal cells trained to perform the expected role in the skin, as happens in reality,' and then 'organizing' these cells in three dimensions to 'reproduce the structure of real skin,' Le Lus clarified.
At this stage, the teams are capable of producing 'about a hundred units' of this skin, which is the result of five years of research. This '100% French breakthrough' paves the way for clinical trials planned 'starting in 2030' at EFS pharmaceutical facilities, as well as 'transitioning to industrial scale for commercialization around 2040,' according to the statement.
Urgo, which is now part of a group of about ten global companies with its own 'cell bank' for artificial skin, plans to establish the necessary industrial base for large-scale production 'after completing this first clinical trial, around 2032.' Furthermore, models of artificial skin are already used worldwide for research purposes, for example, as an alternative to certain animal testing, including cosmetic product testing.